Pharmacovigilance Specialist

Are you passionate about ensuring patient safety and making a positive impact in the pharmaceutical industry? Look no further! Novo Nordisk, a global healthcare company, is seeking a highly motivated and skilled Pharmacovigilance Specialist to join our team. As a leader in diabetes care and other chronic diseases, we are committed to upholding the highest standards of drug safety. In this role, you will play a critical role in our mission by monitoring and evaluating adverse events associated with our products. We are looking for a detail-oriented individual with a strong background in pharmacovigilance and a desire to make a difference in the lives of patients worldwide. If you are ready to take on this exciting challenge, we welcome your application!

• Monitor and evaluate adverse events associated with Novo Nordisk products
• Ensure compliance with global pharmacovigilance regulations and guidelines
• Conduct thorough and timely review of safety data reports
• Collaborate with cross-functional teams to identify and mitigate potential safety risks
• Participate in the development and maintenance of risk management plans
• Provide pharmacovigilance expertise and support to internal and external stakeholders
• Maintain accurate and up-to-date pharmacovigilance documentation and records
• Stay current on industry trends and updates related to drug safety and adverse event reporting
• Contribute to the continuous improvement of pharmacovigilance processes and procedures
• Adhere to ethical standards and maintain patient confidentiality at all times.

According to JobzMall, the average salary range for a Pharmacovigilance Specialist in London, UK is between £40,000 and £60,000 per year. This can vary depending on factors such as experience, education, and the specific company or organization the individual is working for. Some highly experienced and specialized Pharmacovigilance Specialists may earn salaries upwards of £80,000 per year.

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas.